Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Multiple Myeloma* / therapy
  • Receptors, Chimeric Antigen*

Substances

  • idecabtagene vicleucel
  • Receptors, Chimeric Antigen